The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ceftazidime 500 mg powder for solution for injection

Hikma Farmacêutica (Portugal) S.A.PA1217/012/001

Main Information

Trade NameCeftazidime 500 mg powder for solution for injection
Active SubstancesCeftazidime
Dosage FormPowder for solution for injection
Licence HolderHikma Farmacêutica (Portugal) S.A.
Licence NumberPA1217/012/001

Group Information

ATC CodeJ01DD Third-generation cephalosporins
J01DD02 ceftazidime


License statusAuthorised
Licence Issued12/09/2014
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back